SAFE Opioid Prescribing: Goals of Therapy, Monitoring and Patient Education of ER/LA Opioids
SAFE Opioid Prescribing | Strategies. Assessment. Fundamentals. Education
Today, clinicians are faced with the challenge of adequately treating a large number of patients with acute and chronic pain, while mitigating the risks associated with treatment. Our ability to manage pain, now competes against the crisis of opioid abuse and adverse outcomes such as addiction, unintentional overdose, and death, resulting from inappropriate prescribing, abuse, and misuse of opioids.
These complexities require clinicians to have a strong understanding of all options for pain management including non-pharmacologic and non-opioid options, as well as when to appropriately consider opioid agents when other non-opioid approaches have proven unsuccessful in alleviating pain and the benefits outweigh the risks.
The SAFE Opioid Risk Evaluation and Mitigation Strategy (REMS) symposium is designed to fulfill on specific requirements put forth by the FDA Education Blueprint for HCPs Involved in the Treatment and Monitoring of Patients with Pain. Three evidence-based CME modules will address topics such as; the fundamentals of pain management, assessment of patients in pain, identifying and mitigating risk factors for abuse and addiction, and how to appropriately integrate opioid analgesics into a pain treatment plan individualized to the needs of the patient.
Additional topics to be covered include, tools to manage patients on opioids analgesics in pain settings, including initiating therapy, titrating and discontinuing use, as well as strategies to counsel patients on safe use, disposal, and ways to identify and manage opioid use disorder or addiction.
Complete the entire SAFE Opioid Prescribing activity to receive your training completion certificate!
Speakers Bureau for Allergan, Inc., Depomed, Inc., Janssen Pharmaceuticals, Inc., Millennium Laboratories, LLC, and XenoPort, Inc. Advisory Board member for Acorda Therapeutics, Inc., AstraZeneca Pharmaceuticals LP, Depomed, Inc., Insys Therapeutics Inc., Nektar Therapeutics, Pfizer Inc., Purdue Pharma L.P., QRX Pharma Ltd., Teva Pharmaceuticals Industries Ltd., and XenoPort, Inc. Receives research support from Eli Lilly and Company, Endo Pharmaceuticals Inc., and Forest Laboratories, Inc.
Advisory Board member for Depomed, Inc., Insys Therapeutics Inc., Iroko Pharmaceuticals, LLC, Mallinckrodt Pharmaceuticals, Nektar Therapeutics, Purdue Pharma L.P., Teva Pharmaceuticals Industries Ltd., and Zogenix, Inc. Consultant for Purdue Pharma L.P., Teva Pharmaceuticals Industries Ltd., and Zogenix, Inc. Speakers Bureau member for Depomed, Inc., Iroko Pharmaceuticals, LLC, Johnson & Johnson, Purdue Pharma L.P., Teva Pharmaceuticals Industries Ltd., and Zogenix, Inc.
Speakers Bureau honoraria from Endo Pharmaceuticals, Covidien, Nektar, Pfizer and Purdue. Consultant honoraria from Alere and Shionogi.
Advisory Board member for AstraZeneca Pharmaceuticals LP, Collegium Pharmaceutical, Inc., Depomed, Inc., Inspirion Pharmaceuticals, LLC, Iroko Pharmaceuticals, LLC, Janssen Pharmaceuticals, Inc., Kaléo, Inc., Mallinckrodt Pharmaceuticals, Millennium Laboratories, LLC, Pfizer Inc., Salix Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc., and Zogenix, Inc. Owns stock in BioSpecifics Technologies Corp., Galena Biopharma, Inc., Johnson & Johnson, Nektar Therapeutics, and Protein Design Labs, Inc.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies. Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Extended-Release/Long-Acting Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration.
Miller Medical Communications
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.
Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.